Andrew Scott
Director, Andrew Scott Lab
Andrew Scott Lab Ludwig Center at Melbourne
Ludwig Institute for Cancer Research
Australia
Biography
Throughout my research career as a translational clinician / scientist I have had an abiding interest in the mechanisms of tumour cell growth, and the development of innovative strategies to improve diagnosis and therapy of cancer. The areas of my major research focus have been in the definition and characterisation of antigen / receptor targets for cancer therapy; signalling and metabolic pathways in cancer cells; antibody-based therapy and immune regulation of tumours, and molecular imaging of cancer. The particular emphasis of my laboratory research is colorectal cancer. I have also developed a translational program for extension of our laboratory discoveries into the clinic leading 10 novel antibodies / recombinant proteins successfully through preclinical development, humanisation, production / regulatory compliance, and first-in-human and Phase I/II trials in cancer patients. This program has made a number of key contributions to the field and resulted in 15 patents and our successful licencing of 7 discoveries to Biotech and Pharma.
Research Interest
Tumour cell growth, diagnosis and therapy of cancer, signalling and metabolic pathways in cancer cells, molecular imaging of cancer
Publications
-
Tauro, Bow J., et al. "Comparison of ultracentrifugation, density gradient separation, and immunoaffinity capture methods for isolating human colon cancer cell line LIM1863-derived exosomes." Methods 56.2 (2012): 293-304.
-
Davis, Ian D., et al. "Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans." Proceedings of the National Academy of Sciences of the United States of America 101.29 (2004): 10697-10702.
-
Scott, Andrew M., Jedd D. Wolchok, and Lloyd J. Old. "Antibody therapy of cancer." Nature reviews. Cancer 12.4 (2012): 278.
